



国内版 国际版

Prolonged use of bedaquiline in two patients with pulmonary extens



ALL IMAGES VIDEOS

47,300 Results Any time ▾

## Outcomes of Bedaquiline Treatment in Patients with ...

<https://wwwnc.cdc.gov/eid/article/25/5/18-1823> ▾

**Bedaquiline** is recommended by the World Health Organization for the treatment of multidrug-resistant (MDR) and **extensively** drug-resistant (XDR) **tuberculosis** (TB). We pooled data from 5 cohorts of **patients** treated with **bedaquiline** in France, Georgia, Armenia, and South Africa and in a multicountry study. The rate of culture conversion to negative at 6 months (by the end of 6 months of treatment ...

## Use of bedaquiline in the treatment of a patient with ...

<https://www.researchgate.net/publication/319355277...>

Request PDF | **Use of bedaquiline** in the treatment of a **patient** with **extensively** Drug-Resistant **pulmonary tuberculosis** | A 27-year-old man from the former Soviet Union with unremarkable medical ...

### PEOPLE ALSO ASK

Is bedaquiline a QT-prolonging drug?



Is bedaquiline fumarate safe for TB patients?



Can bedaquiline cause renal impairment?



Is bedaquiline safe for lung cavitation?



Feedback

## [PDF] Bedaquiline in the treatment of multidrug- and extensively ...

<https://erj.ersjournals.com/content/erj/47/2/564.full.pdf>

**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 60219

**Manuscript Type:** CASE REPORT

**Prolonged use of bedaquiline in two patients with pulmonary extensively drug-resistant tuberculosis: Two case report**

36-week bedaquiline treatment for XDR-TB

#### Abstract

##### BACKGROUND

Bedaquiline is among the prioritized drugs recommended by the World Health Organization for the treatment of extensively drug-resistant tuberculosis (XDR-TB). Many patients cannot achieve better clinical improvement after bedaquiline is stopped at 24-week. However, there is no recommendation or guideline on bedaquiline administration beyond 24 wk, which is an important consideration when balancing the

benefit of treatment for XDR-TB against the uncertain safety concerning the long-

#### Match Overview

1

Crossref 12 words

Domingo Palmero, Pablo González Montaner, Mónica Cufre, Ana García, Marisa Vescovo, Susana Poggi, "First Series of

<1%

国内版 国际版

Prolonged use of bedaquiline in two patients with pulmonary exten:



ALL IMAGES VIDEOS

35,400 Results

Any time ▾

## Outcomes of Bedaquiline Treatment in Patients with ...

<https://wwwnc.cdc.gov/eid/article/25/5/18-1823> ▾

Bedaquiline is recommended by the World Health Organization for the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). We pooled data from 5 cohorts of patients treated with bedaquiline in France, Georgia, Armenia, and South Africa and in a multicountry study. The rate of culture conversion to negative at 6 months (by the end of 6 months of treatment ...

## Bedaquiline and Delamanid Treatment in Drug-Resistant TB

[https://www.medscape.com/viewarticle/888379\\_1](https://www.medscape.com/viewarticle/888379_1) ▾

May 21, 2020 · Table 1. Demographics and clinical history of patients with pulmonary extensively drug-resistant TB treated with bedaquiline and delamanid\* Pt no.

### PEOPLE ALSO ASK

Is bedaquiline a QT-prolonging drug? ▾

Is bedaquiline safe for lung cavitation? ▾

Is bedaquiline safe? ▾

Feedback

## Bedaquiline and Delamanid Combination Treatment of 5 ...

<https://wwwnc.cdc.gov/eid/article/23/10/17-0834> ▾

We report the experiences of 5 patients taking bedaquiline with delamanid in combination: 1 patient was cured; 3 culture converted, with 2 continuing and 1 changing therapy; and 1 died from respiratory insufficiency. For 2 patients, QT-interval prolongation but no arrhythmias occurred. Use of this therapy is justified for patients with limited options.

## Bedaquiline for the Treatment of Multidrug-resistant ...

<https://academic.oup.com/cid/article-abstract/71/4/1010/5574390> ▾

Multidrug-resistant tuberculosis (MDR TB), defined as TB with an isolate resistant to at least isoniazid (INH) and rifampin (RIF), and extensively drug-resistant TB (XDR TB), defined as MDR TB with additional resistance to a fluoroquinolone and an injectable agent, threaten communities around the world and pose